Treatment of primary systemic amyloidosis (AL): Role of intensive and standard therapy

Clinical Advances in Hematology and Oncology

Volumn 10, Issue 10, 2012, Pages 644-651

  Sher, Taimur ^a   Hayman, Suzanne R ^b   Gertz, Morie A ^b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Amyloidosis; Chemotherapy; Immunoglobulin light chain; Stem cell transplantation

Indexed keywords

BORTEZOMIB; CARFILZOMIB; COLCHICINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; IXAZOMIB CITRATE; LENALIDOMIDE; MELPHALAN; POMALIDOMIDE; PREDNISONE; THALIDOMIDE;

AMYLOIDOSIS; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CONGESTIVE HEART FAILURE; DRUG DOSE REDUCTION; DRUG MEGADOSE; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL HEMORRHAGE; HEART ARREST; HUMAN; INTENSIVE CARE; KIDNEY FAILURE; MORTALITY; MULTICENTER STUDY (TOPIC); MULTIPLE MYELOMA; MULTIPLE ORGAN FAILURE; MYELOABLATIVE CONDITIONING; NEUROPATHY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REDUCED INTENSITY CONDITIONING; RISK; SINGLE DRUG DOSE; STEM CELL TRANSPLANTATION; SURVIVAL; SYSTEMIC THERAPY; TREATMENT RESPONSE;

AMYLOIDOSIS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; BORONIC ACIDS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MELPHALAN; MYELOABLATIVE AGONISTS; MYOCARDIUM; PYRAZINES; STEROIDS; SURVIVAL ANALYSIS; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84868268610     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Bhat A, Selmi C, Naguwa SM, Cheema GS, Gershwin ME. Currents concepts on the immunopathology of amyloidosis. Clin Rev Allergy Immunol. 2010;38:97-106.
2. Picken MM. Amyloidosis-where are we now and where are we heading? Arch Pathol Lab Med. 2010;134:545-551.
3. Baden EM, Sikkink LA, Ramirez-Alvarado M. Light chain amyloidosis-current findings and future prospects. Curr Protein Pept Sci. 2009;10:500-508.
4. Kyle RA, Linos A, Beard CM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood. 1992;79:1817-1822.
5. Comenzo RL, Zhang Y, Martinez C, Osman K, Herrera GA. The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden. Blood. 2001;98:714-720.
6. Kumar S, Gertz M, Lacy M, et al. Recent improvements in survival in light chain amyloidosis and the importance of an early mortality risk score. Blood. 2010;19:116-121.
7. Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22:3751-3757.
8. Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood. 2001;97:2900-2902.
9. Kumar SK, Dispenzieri A, Lacy MQ, et al. Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. Am J Hematol. 2011;86:251-255.
10. Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30:989-995.
11. Palladini G, Kyle RA, Larson DR, Therneau TM, Merlini G, Gertz MA. Multicentre versus single centre approach to rare diseases: the model of systemic light chain amyloidosis. Amyloid. 2005;12:120-126.
12. Dispenzieri A, Lacy MQ, Katzmann JA, et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2006;107:3378-3383.
13. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Am J Hematol. 2005;79:319-328.
14. Jones NF, Hilton PJ, Tighe JR, Hobbs JR. Treatment of "primary" renal amyloidosis with melphalan. Lancet. 1972;2:616-619.
15. Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997;336:1202-1207.
16. Skinner M, Anderson J, Simms R, et al. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med. 1996;100:290-298.
17. Gertz MA, Kyle RA, Greipp PR. Response rates and survival in primary systemic amyloidosis. Blood. 1991;77:257-262.
18. Dhodapkar MV, Jagannath S, Vesole D, et al. Treatment of AL-amyloidosis with dexamethasone plus alpha interferon. Leuk Lymphoma. 1997;27:351-356.
19. Gertz MA, Lacy MQ, Lust JA, Greipp PR, Witzig TE, Kyle RA. Phase II trial of high-dose dexamethasone for previously treated immunoglobulin light-chain amyloidosis. Am J Hematol. 1999;61:115-119.
20. Gertz MA, Lacy MQ, Lust JA, Greipp PR, Witzig TE, Kyle RA. Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis. Med Oncol. 1999;16:104-109.
21. Palladini G, Anesi E, Perfetti V, et al. A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. Br J Hematol. 2001;113:1044-1046.
22. Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood. 2004;103:2936-2938.
23. Sanchorawala V, Seldin DC, Berk JL, Sloan JM, Doros G, Skinner M. Oral cyclic melphalan and dexamethasone for patients with AL amyloidosis. Clin Lymphoma Myeloma Leuk. 2010;10:469-472.
24. Seldin DC, Choufani EB, Dember LM, et al. Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. Clin Lymphoma. 2003;3:241-246.
25. Wechalekar AD, Goodman HJ, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood. 2007;109:457-464.
26. Sanchorawala V, Wright DG, Rosenzweig M, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood. 2007;109:492-496.
27. Palladini G, Russo P, Foli A, et al. Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide. Ann Hematol. 2012;91:89-92.
28. Moreau P, Jaccard A, Benboubker L, et al. Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. Blood. 2010;116:4777-4782.
29. Kumar SK, Hayman SR, Buadi FK, et al. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood. 2012;119:4860-4867.
30. Dispenzieri A, Buadi F, Laumann K, et al. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood. 2012;119:5397-5404.
31. Wechalekar AD, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica. 2008;93:295-298.
32. Reece DE, Sanchorawala V, Hegenbart U, et al. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 doseescalation study. Blood. 2009;114:1489-1497.
33. Kastritis E, Wechalekar AD, Dimopoulos MA, et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol. 2010;28:1031-1037.
34. Lamm W, Willenbacher W, Lang A, et al. Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis. Ann Hematol. 2011;90:201-206.
35. Schonland SO, Lokhorst H, Buzyn A, et al. Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation. Blood. 2006;107:2578-2584.
36. Comenzo RL, Vosburgh E, Simms RW, et al. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients. Blood. 1996;88:2801-2806.
37. Sanchorawala V, Wright DG, Seldin DC, et al. An overview of the use of highdose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant. 2001;28:637-642.
38. Moreau P, Leblond V, Bourquelot P, et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Hematol. 1998;101:766-769.
39. Gillmore JD, Apperley JF, Craddock CE, et al. High-dose melphalan and stem cell rescue for AL amyloidosis. In: Kyle RA, Gertz MA, eds. Amyloid and Amyloidosis 1998: The Proceedings of the VIIIth International Symposium on Amyloidosis August 7-11, 1998, Rochester, Minnesota, USA. Pearl River, New York: The Parthenon Publishing Group; 1999:102-104.
40. Gertz MA, Lacy MQ, Dispenzieri A, et al. Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report. Leuk Lymphoma. 2010;51:2181-2187.
41. Dispenzieri A, Lacy MQ, Kyle RA, et al. Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol. 2001;19:3350-3356.
42. Jaccard A, Moreau P, Leblond V, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med. 2007;357:1083-1093.
43. Mhaskar R, Kumar A, Behera M, Kharfan-Dabaja MA, Djulbegovic B. Role of highdose chemotherapy and autologous hematopoietic cell transplantation in primary systemic amyloidosis: a systematic review. Biol Blood Marrow Transplant. 2009;15:893-902.
44. Sanchorawala V, Skinner M, Quillen K, Finn KT, Doros G, Seldin DC. Longterm outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood. 2007;110:3561-3563.
45. Kyle RA, Gertz MA, Greipp PR, et al. Long-term survival (10 years or more) in 30 patients with primary amyloidosis. Blood. 1999;93:1062-1066.
46. Dispenzieri A, Kyle RA, Lacy MQ, et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a casecontrol study. Blood. 2004;103:3960-3963.
47. Gertz MA, Dispenzieri A. Immunoglobulin light-chain amyloidosis: growing recognition, new approaches to therapy, active clinical trials. Oncology (Williston Park). 2012;26:152-161.
48. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood. 2002;99:4276-4282.